Scholarlink

<p>Diffuse large B cell lymphoma (DLBCL) is one of the most aggressive hematological diseases. Angiogenesis is one of the important aspects of DLBCL, providing the basics for tumor growth and metastasis. In this review, we discussed the Vascular Endothelial Growth Factor (VEGF) polymorphisms, the role of VEGF expression and angiogenesis in disease pathophysiology, and the association of VEGF and other angiogenesis parameters in the prognosis of this non-Hodgkin lymphoma. A comprehensive literature search was conducted using PubMed, Scopus, and Google Scholar to identify studies related to VEGF and angiogenesis in DLBCL. Keywords included “VEGF,” “angiogenesis,” “DLBCL,” and “anti-angiogenesis therapy.” Relevant articles from the past two decades were prioritized for inclusion. Based on the majority of previous studies, VEGF and the higher score of angiogenesis may play a role in the disease’s aggressiveness. Seemingly, an abnormal vascular network may assist tumor cells in evading the immune system. Regarding improving anti-angiogenesis therapy, it could be considered one member of the combination treatment for DLBCL. The numerous studies highlighting the significance of angiogenesis in lymphoma, yet failing to achieve substantial improvements in patient survival, underscore the need for further research in this field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The New Insight on the Significance of Vascular Endothelial Growth Factor in Anti-angiogenesis Therapy for Diffuse Large B Cell Lymphoma

  • 期刊论文

  • 发表日期：

    2025年9月20日

查看全文
  • Farzaneh Tavakoli,
  • Maryam Mehravar,
  • Amirhossein Izadpanah,
  • Hamid Rezvani,
  • Maryam Salimi,
  • Zeinab Kaboli,
  • Mahshid Mehdizadeh,
  • Elham Roshandel

摘要

Diffuse large B cell lymphoma (DLBCL) is one of the most aggressive hematological diseases. Angiogenesis is one of the important aspects of DLBCL, providing the basics for tumor growth and metastasis. In this review, we discussed the Vascular Endothelial Growth Factor (VEGF) polymorphisms, the role of VEGF expression and angiogenesis in disease pathophysiology, and the association of VEGF and other angiogenesis parameters in the prognosis of this non-Hodgkin lymphoma. A comprehensive literature search was conducted using PubMed, Scopus, and Google Scholar to identify studies related to VEGF and angiogenesis in DLBCL. Keywords included “VEGF,” “angiogenesis,” “DLBCL,” and “anti-angiogenesis therapy.” Relevant articles from the past two decades were prioritized for inclusion. Based on the majority of previous studies, VEGF and the higher score of angiogenesis may play a role in the disease’s aggressiveness. Seemingly, an abnormal vascular network may assist tumor cells in evading the immune system. Regarding improving anti-angiogenesis therapy, it could be considered one member of the combination treatment for DLBCL. The numerous studies highlighting the significance of angiogenesis in lymphoma, yet failing to achieve substantial improvements in patient survival, underscore the need for further research in this field.